Solid-phase synthesis of 5'-triphosphate 2'-5'-oligoadenylates analogs with 3'-O-biolabile groups and their evaluation as RNase L activators and antiviral drugs.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Bioorganic & Medicinal Chemistry

• Publication date

  2013-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmc.2013.06.008PMID 23810677
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Advances in Quantitative FRET‐Based Methods for Studying Nucleic Acids

  2012cited by this paper
• Synthesis and Enzymatic Deprotection of Fully Protected 2′‐5′ Oligoadenylates (2‐5A): Towards a Prodrug Strategy for Short 2‐5A

  2012cited by this paper
• Synthesis, pairing, and cellular uptake properties of C(6')-functionalized tricyclo-DNA.

  2012cited by this paper
• Activation of human RNase L by 2'- and 5'-O-methylphosphonate-modified oligoadenylates.

  2012cited by this paper
• Streamlined process for the chemical synthesis of RNA using 2'-O-thionocarbamate-protected nucleoside phosphoramidites in the solid phase.

  2011cited by this paper
• New light labile linker for solid phase synthesis of 2'-O-acetalester oligonucleotides and applications to siRNA prodrug development.

  2011cited by this paper
• Simultaneous Detection of Influenza A, Influenza B, and Respiratory Syncytial Viruses and Subtyping of Influenza A H3N2 Virus and H1N1 (2009) Virus by Multiplex Real-Time PCR

  2011cited by this paper
• Synthesis and Enzymatic Deprotection of Biodegradably Protected Dinucleoside‐2′,5′‐monophosphates: 3‐(Acetyloxy)‐2,2‐bis(ethoxycarbonyl)propyl Phosphoesters of 3′‐O‐(Acyloxymethyl)adenylyl‐2′,5′‐adenosines

  2011cited by this paper
• Synthesis and preliminary evaluation of pro-RNA 2'-O-masked with biolabile pivaloyloxymethyl groups in an RNA interference assay.

  2011cited by this paper
• Efficient solid-phase chemical synthesis of 5'-triphosphates of DNA, RNA, and their analogues.

  2010cited by this paper
• 5'-O-dephosphorylated 2',5'-oligoadenylate (2-5A) with 8-methyladenosine at the 2'-terminus activates human RNase L.

  2010cited by this paper
• Assessment of heat-sensitive thiophosphate protecting groups in the development of thermolytic DNA oligonucleotide prodrugs

  2010cited by this paper
• Assessment of new 2'-O-acetalester protecting groups for regular RNA synthesis and original 2'-modified proRNA.

  2009cited by this paper
• The design, synthesis and evaluation of hypoxia-activated pro-oligonucleotides.

  2009cited by this paper
• A base-labile group for 2'-OH protection of ribonucleosides: a major challenge for RNA synthesis.

  2008cited by this paper
• Diverse functions of RNase L and implications in pathology.

  2007cited by this paper
• Biologically Stable 2‐5A Analogues containing 3′‐O,4′‐C‐bridged Adenosine as Potent RNase L Agonists

  2007cited by this paper
• A scientific journey through the 2-5A/RNase L system.

  2007cited by this paper
• Viral Encounters with 2′,5′-Oligoadenylate Synthetase and RNase L during the Interferon Antiviral Response

  2007cited by this paper
• RSV604, a Novel Inhibitor of Respiratory Syncytial Virus Replication

  2007cited by this paper
• Activation of murine RNase L by isopolar 2'-phosphonate analogues of 2',5' oligoadenylates.

  2006cited by this paper
• Prodrug approaches of nucleotides and oligonucleotides.

  2006cited by this paper
• First evaluation of acyloxymethyl or acylthiomethyl groups as biolabile 2'-O-protections of RNA.

  2006cited by this paper
• Thermolytic CpG-containing DNA oligonucleotides as potential immunotherapeutic prodrugs

  2005cited by this paper
• Structural basis for recognition of 2′,5′‐linked oligoadenylates by human ribonuclease L

  2004cited by this paper
• Synthesis of 2',5'-oligoadenylate analogs containing an adenine acyclonucleoside and their ability to activate human RNase L.

  2004cited by this paper
• Development of a Real-Time Reverse Transcriptase PCR Assay for Type A Influenza Virus and the Avian H5 and H7 Hemagglutinin Subtypes

  2002cited by this paper
• Chemistry and biochemistry of 2',5'-oligoadenylate-based antisense strategy.

  2001cited by this paper
• Lipophilic pro-oligonucleotides are rapidly and efficiently internalized in HeLa cells.

  1999cited by this paper
• The 2–5 A system: Modulation of viral and cellular processes through acceleration of RNA degradation

  1998cited by this paper
• The pro-oligonucleotide approach: solid phase synthesis and preliminary evaluation of model pro-dodecathymidylates.

  1998cited by this paper
• Potent inhibition of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA.

  1998cited by this paper
• Hydroquinone-O,O'-diacetic acid ('Q-linker') as a replacement for succinyl and oxalyl linker arms in solid phase oligonucleotide synthesis.

  1997cited by this paper
• Synthesis and biological activities of a phosphorodithioate analog of 2',5'-oligoadenylate.

  1995cited by this paper
• Prodrugs of Oligonucleotides: The Acyloxyalkyl Esters of Oligodeoxyribonucleoside Phosphorothioates

  1995cited by this paper
• An improved procedure for derivatization of controlled-pore glass beads for solid-phase oligonucleotide synthesis

  1990cited by this paper
• Phosphorothioate analogues of (2'-5')(A)4: agonist and antagonist activities in intact cells.

  1990cited by this paper
• Phosphorothioate analogues of 2',5'-oligoadenylate. Enzymatic synthesis, properties, and biological activities of 2',5'-phosphorothioates from adenosine 5'-O-(2-thiotriphosphate) and adenosine 5'-O-(3-thiotriphosphate).

  1987cited by this paper
• Analogue inhibitor of 2‐5A action: effect on the interferon‐mediated inhibition of encephalomyocarditis virus replication.

  1985cited by this paper
• pppA2'p5'A2'p5'A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells.

  1978cited by this paper
• Virus interference. I. The interferon

  1957cited by this paper

• Access to High‐Purity 7mG‐cap RNA in Substantial Quantities by a Convenient All‐Chemical Solid‐Phase Method

  2023cites this paper
• Targeting Host Factors to Treat West Nile and Dengue Viral Infections

  2014cites this paper
• Innovative Chemistry for Synthesis of Regular RNA, 5′-Triphosphate RNA, or 5′-Capped RNA

  2014cites this paper